Induction of Tolerance Towards Solid Organ Allografts Using Hematopoietic Cell Transplantation in Large Animal Models
- PMID: 32944710
- PMCID: PMC7494220
- DOI: 10.21926/obm.transplant.1903080
Induction of Tolerance Towards Solid Organ Allografts Using Hematopoietic Cell Transplantation in Large Animal Models
Abstract
Background: The application of hematopoietic cell transplantation for induction of immune tolerance has been limited by toxicities associated with conditioning regimens and to graft-versus-host disease (GVHD). Decades of animal studies have culminated into sufficient control of these two problems, making immune tolerance a viable alternative to life-long application of immunosuppressive drugs to prevent allograft rejection.
Methods: Studies in mice have paved the way for the application of HCT with limited toxicity in large animal models. Resultant studies in the pig, dog, and ultimately the nonhuman primate have led to appropriate methods for achieving nonmyeloablative irradiation protocols, dose, and timing of post-grafting immunosuppressive drugs, monoclonal antibody therapy, and biologicals for costimulatory molecule blockade. The genetics field has been extensively evaluated in appreciation of the ultimate need to obtain organs from MHC-mismatched unrelated donors.
Results: Nonmyeloablative conditioning regimens have been shown to be successful in inducing immune tolerance across all three animal models. Postgrafting immunosuppression is also important in assuring sustained donor hematopoiesis for tolerance. Donor chimerism need not be permanent to establish stable engraftment of donor organs, thereby essentially eliminating the risk of GVHD. Using nonmyeloablative HCT with monoclonal antibody immunosuppression, the kidney has been successfully transplanted in MHC-mismatched nonhuman primates.
Conclusions: Nonmyeloablative HCT for the establishment of temporary mixed chimerism has led to the establishment of stable tolerance against solid organ allografts in large animal models. The kidney, considered a tolerogenic organ, has been successfully transplanted in the clinic. Other organs such as heart, lung, and vascularized composite allografts (face and hands), remain distant possibilities. Further study in large animal models will be required to improve tolerance against these organs before success can be attained in the clinic.
Keywords: Tolerance; hematopoietic cell transplantation; large animal model; organ transplantation; preclinical.
Conflict of interest statement
Competing Interests The authors have declared that no competing interests exist.
Figures

Similar articles
-
Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.Biol Blood Marrow Transplant. 2001;7(12):646-55. doi: 10.1053/bbmt.2001.v7.pm11787527. Biol Blood Marrow Transplant. 2001. PMID: 11787527
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model.Transplantation. 2006 Aug 15;82(3):332-9. doi: 10.1097/01.tp.0000228908.10775.b0. Transplantation. 2006. PMID: 16906030
-
Toward Development of the Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Nonhuman Primates.Plast Reconstr Surg. 2020 Apr;145(4):757e-768e. doi: 10.1097/PRS.0000000000006676. Plast Reconstr Surg. 2020. PMID: 32221215
-
Facilitating cells as a venue to establish mixed chimerism and tolerance.Pediatr Transplant. 2003 Oct;7(5):348-57. doi: 10.1034/j.1399-3046.2003.00100.x. Pediatr Transplant. 2003. PMID: 14738294 Review.
Cited by
-
Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.Vet Comp Oncol. 2020 Dec;18(4):471-483. doi: 10.1111/vco.12608. Epub 2020 May 26. Vet Comp Oncol. 2020. PMID: 32385957 Free PMC article. Review.
-
Basics and Art of Immunosuppression in Liver Transplantation.J Clin Exp Hepatol. 2024 May-Jun;14(3):101345. doi: 10.1016/j.jceh.2024.101345. Epub 2024 Jan 24. J Clin Exp Hepatol. 2024. PMID: 38450290 Free PMC article. Review.
-
Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation.Vet Med Sci. 2021 Nov;7(6):2156-2171. doi: 10.1002/vms3.601. Epub 2021 Aug 14. Vet Med Sci. 2021. PMID: 34390541 Free PMC article. Review.
-
Immunogenicity and tolerance induction in vascularized composite allotransplantation.Front Transplant. 2024 Feb 13;3:1350546. doi: 10.3389/frtra.2024.1350546. eCollection 2024. Front Transplant. 2024. PMID: 38993748 Free PMC article. Review.
References
-
- Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clinical Transplantation. 2006;20(4):401–409. - PubMed
-
- Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6(9):511–519. - PubMed
-
- Hachem RR. Lung allograft rejection: diagnosis and management. Curr Opin Organ Transplant. 2009;14(5):477–482. - PubMed
-
- Hornick P, Rose M. Chronic rejection in the heart. Methods Mol Biol. 2006;333:131–144. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials